AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
| Revenue (TTM) | $66.01B |
| Gross Profit (TTM) | $48.67B |
| EBITDA | $31.85B |
| Operating Margin | 39.60% |
| Return on Equity | 62.30% |
| Return on Assets | 10.70% |
| Revenue/Share (TTM) | $37.32 |
| Book Value | $-2.59 |
| Price-to-Book | 50.46 |
| Price-to-Sales (TTM) | 7.80 |
| EV/Revenue | 8.78 |
| EV/EBITDA | 24.71 |
| Quarterly Earnings Growth (YoY) | 2282.00% |
| Quarterly Revenue Growth (YoY) | 10.30% |
| Shares Outstanding | $1.77B |
| Float | $1.76B |
| % Insiders | 0.11% |
| % Institutions | 77.41% |
Volatility is currently expanding
A fat yield means nothing if the check bounces. Five payers across telecom, tobacco, pharma, real estate and pipelines show how to test coverage, and one of them carries a debt pile that could threaten its raise streak.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Four dividend stocks just delivered strong earnings, but free cash flow and balance sheet strength separate the ones built to keep raising payouts from the ones that just look good on paper.
AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that already looks stretched.
– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes – A digital image analysis evaluating glabellar line severity and brow position following treatment with investigational trenibotulinumtoxinE (trenibotE) and BOTOX ® Cosmetic (onabotulinumtoxinA) will be presented during the Cosmetic Oral Abstract Presentations: Top Ten session – Expert panel to explore shifting consumer expectations, common misconceptions and medical weight loss in aesthetics, drawing on insights from the Allergan Aesthetics "What Consumers Really Want" report IRVINE, Calif., Nov. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, underscoring the company's continued investment in generating scientific evidence to inform care across multiple aesthetic categories.
AbbVie TodayABBVAbbVie$288.82 -6.07 (-2.06%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$190.75▼$298.74Dividend Yield2.40%P/E Ratio49.69Price Target$285.89Add to WatchlistBelieve it or not, Humira still drives headlines for AbbVie NYSE: ABBV, despite contributing little to the company's growth.
AbbVie survived its loss of Humira, and its profits are soaring. J&J's streamlining efforts are paying off.
AbbVie raises its 2026 revenue and earnings outlook as Skyrizi, Rinvoq and neuroscience growth fuel momentum, while oncology milestones shape prospects.
AbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products. Bristol Myers Squibb offers a high-margin portfolio focused on oncology and hematology with a significantly lower valuation multiple.
When you're drawing income from a portfolio, the check size matters less than whether it keeps coming every year. A blue-chip payout is funded by free cash flow left over after the business reinvests in itself.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABBV and any ticker you trade — then tracks every position and per-strategy win rate.
